

AMENDMENTS TO THE CLAIMS

The following listing of claims replaces all previous versions, and listings, of claims in this application.

Listing of Claims

1. **(Currently amended)** An oligopeptide consisting of ~~having~~ the amino acid sequence:
Arg-nL-nL-nL-Arg-nL-nL-nL-Gly-Tyr (SEQ ID NO:13).
2. **(Previously presented)** The oligopeptide according to Claim 1 wherein one or more of the amino acids of said oligopeptide are D isomers.
3. **(Previously presented)** The oligopeptide according to Claim 2, wherein all the amino acids of said oligopeptide, other than glycine, are D isomers
4. **(Previously presented)** The oligopeptide according to Claim 1, wherein the terminal carboxyl group of said oligopeptide is amidated
5. **(Previously presented)** The oligopeptide according to Claim 1, wherein said oligopeptide is in salt form
6. **(Previously presented)** The oligopeptide according to Claim 1, wherein the terminal carboxyl group of said oligopeptide is the acetate salt of an amide.
7. **(Currently amended)** An oligopeptide consisting of ~~having~~ the structural formula:
H-(D)Arg-(D)nL-(D)nL-(D)nL-(D)Arg-(D)nL-(D)nL-(D)nL-Gly-(D)Tyr-NH₂
8. **(Previously presented)** An oligopeptide according to Claim 7, where said oligopeptide is in salt form.
- 9-10. **(Canceled)**
11. **(Previously presented)** The oligopeptide according to Claim 2, wherein the terminal carboxyl group of said oligopeptide is amidated

12. (Previously presented) The oligopeptide according to Claim 3, wherein the terminal carboxyl group of said oligopeptide is amidated.

13. (Previously presented) The oligopeptide according to Claim 2, wherein said oligopeptide is in salt form

14. (Previously presented) The oligopeptide according to Claim 3, wherein said oligopeptide is in salt form

15. (Previously presented) The oligopeptide according to Claim 4, wherein said oligopeptide is in salt form

16 - 17. (Canceled)

18. (Previously presented) The oligopeptide according to Claim 2, wherein the terminal carboxyl group of said oligopeptide is the acetate salt of an amide

19. (Previously presented) The oligopeptide according to Claim 3, wherein the terminal carboxyl group of said oligopeptide is the acetate salt of an amide.

20. (Previously presented) The oligopeptide according to Claim 4, wherein the terminal carboxyl group of said oligopeptide is the acetate salt of an amide.

21. (Previously presented) The oligopeptide according to Claim 5, wherein the terminal carboxyl group of said oligopeptide is the acetate salt of an amide.

22-28. (Canceled)

29. (Previously presented) A pharmaceutical composition comprising an oligopeptide as in any of Claims 1-8 or 11-15 or 18-21, further comprising a pharmaceutically acceptable medium

30. (Previously presented) The pharmaceutical composition according to Claim 29, wherein said pharmaceutically acceptable medium comprises an excipient.

Serial No. 10/780,321

Filing Date: February 17, 2004

31. **(Previously presented)** The pharmaceutical composition according to Claim 30, wherein said excipient comprises mannitol